Louisiana Record

Tuesday, January 21, 2020

Xarelto suit accuses Janssen R&D of negligence, wrongful death

By Robert Hadley | Dec 10, 2015


NEW ORLEANS – The plaintiffs in a class action lawsuit say the makers of Xarelto knowingly sold the product with inadequate testing and warnings.

Dana Beckham, Walter Cheney, Judith Forloines, Addison Forloines, et al filed against Janssen Research and Development, formerly known as Johnson and Johnson Pharmaceutical Research and Development, et al on July 31 in the U.S. District Court for the Eastern District of Louisiana, citing negligence, strict products liability, breach of express warranty, wrongful death and other counts.

According to the complaint, those treated with Xarelto, a blood thinner for stroke prevention, suffered severe and permanent side effects, such as bleeding, shortened life expectancy and loss of earnings. The plaintiffs allege that the defendants fraudulently represented the safety of the drug and concealed the knowledge of the drug's defects.

The plaintiffs seek damages of more than $75,000, including pre- and post-judgment interest and litigation costs. They are represented by attorney Seth Sharrock Webb in St. Louis.

U.S. District Court for the Eastern District of Louisiana Case number 2:15-cv-03129

Want to get notified whenever we write about Janssen Research & Development, LLC ?

Sign-up Next time we write about Janssen Research & Development, LLC, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Janssen Research & Development, LLC